Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 5
2017 1
2018 3
2019 3
2021 3
2022 6
2023 7
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Effect of a combination of pemafibrate and a mild low-carbohydrate diet on obese and non-obese patients with metabolic-associated fatty liver disease.
Suzuki Y, Maekawa S, Yamashita K, Osawa L, Komiyama Y, Nakakuki N, Takada H, Muraoka M, Sato M, Takano S, Fukasawa M, Yamaguchi T, Funayama S, Morisaka H, Onishi H, Enomoto N. Suzuki Y, et al. Among authors: komiyama y. J Gastroenterol Hepatol. 2023 Jun;38(6):921-929. doi: 10.1111/jgh.16154. Epub 2023 Mar 5. J Gastroenterol Hepatol. 2023. PMID: 36811251
Impact of Renal Function on the Prognosis of Patients Receiving Atezolizumab/Bevacizumab Combination Therapy and Lenvatinib Monotherapy for Unresectable Hepatocellular Carcinoma.
Takada H, Yamashita K, Osawa L, Komiyama Y, Nakakuki N, Muraoka M, Suzuki Y, Sato M, Takano S, Fukasawa M, Yamaguchi T, Maekawa S, Takahashi K, Uchimura K, Enomoto N. Takada H, et al. Among authors: komiyama y. Oncology. 2023;101(10):609-623. doi: 10.1159/000531111. Epub 2023 Jun 6. Oncology. 2023. PMID: 37279708
Significance of the autoantibody assay in predicting the development of immune-related adverse events in patients receiving atezolizumab plus bevacizumab combination therapy for unresectable hepatocellular carcinoma.
Takada H, Yamashita K, Osawa L, Komiyama Y, Muraoka M, Suzuki Y, Sato M, Kobayashi S, Yoshida T, Takano S, Maekawa S, Enomoto N. Takada H, et al. Among authors: komiyama y. Hepatol Res. 2024 Feb;54(2):162-173. doi: 10.1111/hepr.13969. Epub 2023 Oct 6. Hepatol Res. 2024. PMID: 37740643
Analysis of direct-acting antiviral-resistant hepatitis C virus haplotype diversity by single-molecule and long-read sequencing.
Yamauchi K, Sato M, Osawa L, Matsuda S, Komiyama Y, Nakakuki N, Takada H, Katoh R, Muraoka M, Suzuki Y, Tatsumi A, Miura M, Takano S, Amemiya F, Fukasawa M, Nakayama Y, Yamaguchi T, Inoue T, Maekawa S, Enomoto N. Yamauchi K, et al. Among authors: komiyama y. Hepatol Commun. 2022 Jul;6(7):1634-1651. doi: 10.1002/hep4.1929. Epub 2022 Mar 31. Hepatol Commun. 2022. PMID: 35357088 Free PMC article.
Spontaneous portosystemic shunt diameter predicts liver function after balloon-occluded retrograde transvenous obliteration.
Tatsumi A, Maekawa S, Osawa L, Katoh R, Komiyama Y, Nakakuki N, Takada H, Matsuda S, Muraoka M, Suzuki Y, Sato M, Takahashi E, Miura M, Amemiya F, Takano S, Fukasawa M, Yamaguchi T, Nakayama Y, Inoue T, Okada H, Araki T, Onishi H, Enomoto N. Tatsumi A, et al. Among authors: komiyama y. JGH Open. 2022 Jan 28;6(2):139-147. doi: 10.1002/jgh3.12712. eCollection 2022 Feb. JGH Open. 2022. PMID: 35155824 Free PMC article.
Deep sequencing analysis of serum hepatitis B virus-RNA during nucleot(s)ide analogue therapy.
Matsuda S, Maekawa S, Komiyama Y, Nakakuki N, Muraoka M, Suzuki Y, Sato M, Tatsumi A, Miura M, Amemiya F, Shindo H, Takano S, Fukasawa M, Yamaguchi T, Nakayama Y, Inoue T, Sato T, Yamashita A, Moriishi K, Enomoto N. Matsuda S, et al. Among authors: komiyama y. Hepatol Res. 2021 Jan;51(1):39-50. doi: 10.1111/hepr.13574. Epub 2021 Jan 11. Hepatol Res. 2021. PMID: 32961003
Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma.
Takada H, Kurosaki M, Nakanishi H, Takahashi Y, Itakura J, Tsuchiya K, Yasui Y, Tamaki N, Takaura K, Komiyama Y, Higuchi M, Kubota Y, Wang W, Okada M, Enomoto N, Izumi N. Takada H, et al. Among authors: komiyama y. PLoS One. 2018 Jun 18;13(6):e0198812. doi: 10.1371/journal.pone.0198812. eCollection 2018. PLoS One. 2018. PMID: 29912922 Free PMC article.
Plasma Renin Activity Predicts Prognosis and Liver Disease-Related Events in Liver Cirrhosis Patients with Ascites Treated by Tolvaptan.
Osawa L, Nakanishi H, Kurosaki M, Kirino S, Inada K, Yamashita K, Hayakawa Y, Sekiguchi S, Wang W, Okada M, Higuchi M, Komiyama Y, Takaura K, Takada H, Kaneko S, Maeyashiki C, Tamaki N, Yasui Y, Tsuchiya K, Itakura J, Takahashi Y, Enomoto N, Izumi N. Osawa L, et al. Among authors: komiyama y. Dig Dis. 2022;40(4):479-488. doi: 10.1159/000518099. Epub 2021 Jul 30. Dig Dis. 2022. PMID: 34348262 Free article.
Significance of serum IP-10/CXCL10 measurement in predicting post-direct acting antiviral treatment liver function in patients with HCV-decompensated liver cirrhosis.
Katoh R, Maekawa S, Osawa L, Komiyama Y, Nakakuki N, Takada H, Matsuda S, Muraoka M, Suzuki Y, Sato M, Tatsumi A, Takano S, Fukasawa M, Yamaguchi T, Nakayama Y, Inoue T, Enomoto N. Katoh R, et al. Among authors: komiyama y. Hepatol Res. 2023 Apr;53(4):280-288. doi: 10.1111/hepr.13861. Epub 2022 Dec 13. Hepatol Res. 2023. PMID: 36445119
27 results